Abstract
Erbin belongs to the LAP protein family. Originally, Erbin was described as a Her2-interacting protein. Recent studies demonstrated that Erbin could inhibit the Ras-mediated activation of the mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB) and transforming growth factor β (TGF-β) signaling pathways. It suggests that Erbin may function as a signaling molecule. The functions of Erbin in determining cell polarity and cell adhesion have been well described. This review mainly focuses on the recent findings in regulation of signaling pathways by Erbin.
Keywords: Erbin, MAPK, ERK, NF-κB, TGF-β, signal transduction, carbonyl termini, epithelial morphogensis, mutagenesis, velocardiofacial syndrome, down regulation
Current Protein & Peptide Science
Title: Erbin, a Negative Regulator in Diverse Signal Pathways
Volume: 11 Issue: 8
Author(s): Dan Liu, Ming Shi, Huijun Duan, Caili Han and Ning Guo
Affiliation:
Keywords: Erbin, MAPK, ERK, NF-κB, TGF-β, signal transduction, carbonyl termini, epithelial morphogensis, mutagenesis, velocardiofacial syndrome, down regulation
Abstract: Erbin belongs to the LAP protein family. Originally, Erbin was described as a Her2-interacting protein. Recent studies demonstrated that Erbin could inhibit the Ras-mediated activation of the mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB) and transforming growth factor β (TGF-β) signaling pathways. It suggests that Erbin may function as a signaling molecule. The functions of Erbin in determining cell polarity and cell adhesion have been well described. This review mainly focuses on the recent findings in regulation of signaling pathways by Erbin.
Export Options
About this article
Cite this article as:
Liu Dan, Shi Ming, Duan Huijun, Han Caili and Guo Ning, Erbin, a Negative Regulator in Diverse Signal Pathways, Current Protein & Peptide Science 2010; 11 (8) . https://dx.doi.org/10.2174/138920310794557673
DOI https://dx.doi.org/10.2174/138920310794557673 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials The Proteins Interacting with Prmt5 in Medaka (Oryzias latipes) Identified by Yeast Two-Hybridization
Protein & Peptide Letters Withanolides: Biologically Active Constituents in the Treatment of Alzheimer’s Disease
Medicinal Chemistry Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Prostaglandins Pathway as a Possible Biological Link Between Cancer and Major Depression
Current Angiogenesis (Discontinued) Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Anti-Cancer Agents in Medicinal Chemistry Should we Target Allergen Protease Activity to Decrease the Burden of Allergic Airway Inflammation?
Inflammation & Allergy - Drug Targets (Discontinued) In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry Melanoma
Current Cancer Therapy Reviews Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Mammalian Cell Competitions, Cell-in-Cell Phenomena and Their Biomedical Implications.
Current Molecular Medicine When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology